Diabetic kidney disease is an important chronic complication in diabetic patients, and has become the most important cause of end-stage renal insufficiency. More and more anti-diabetic drugs are searched, developed and applied to clinic to manage diabetes. A lot of studies have showed that some new types of anti-diabetic drugs have some reno-protections beyond its hypoglycemic effects. In this review, the reno-protection and their mechanisms of new types of anti-drugs such as DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors will be introduced as follow.
摘要： 糖尿病肾脏疾病是糖尿病患者重要的慢性并发症, 目前已成为导致终末期肾功能不全的最重要的原因。近 年来抗糖尿病药物被不断研发和应用于临床, 不少研究显示一些新型抗糖尿病药物在改善糖代谢的同时, 尚存在不同 程度的独立降糖之外的肾脏保护作用。本文重点介绍新型抗糖尿病新药 DPP-4 抑制剂、GLP-1 受体激动剂和 SGLT-2 抑制剂对糖尿病肾脏疾病的影响及其可能的机制。